New stock news | Mandy International's Hong Kong IPO prospectus is invalid
Mandy International submitted its Hong Kong stock prospectus on November 20, 2025, which expired six months later on May 20, 2026. Huatai International was its exclusive sponsor at the time of submission.
The Hong Kong IPO prospectus submitted by Mandy International on November 20, 2025 expired after 6 months on May 20, 2026, with Huatai International as its exclusive sponsor at the time of submission.
According to the previous prospectus, Mandy International is a leading professional consumer healthcare company in China, dedicated to developing and providing comprehensive and long-term solutions for skin health and weight management. The company mainly focuses on the hair health sector within the broader skin health industry and has established a leading position in this field.
According to data from Zhoushi Consulting, based on retail sales, Mandy International's flagship product, the Mandy series of minoxidil hair loss treatment products, has ranked first in the Chinese hair loss drug market and minoxidil drug market for ten consecutive years since 2014, with market shares of approximately 57% and 71% in these two markets in 2024 respectively.
Related Articles
.png)
HK Stock Market Move | LAOPU GOLD (06181) falls by more than 5% again. Institutions point out that the short-term data of SKP Mall cannot represent the overall performance of same-store sales.
HK Stock Market Move | Scarce Resources (09936) surged over 16% this week, with the stock price up over 50% since the beginning of the week, validating the potential of the tantalum and niobium track in high-end prosperity verification.
Jilin Province Xidian Pharmaceutical Sci-Tech Development (301130.SZ) subsidiary obtains drug registration certificate for Vitamin B6 injection.
HK Stock Market Move | LAOPU GOLD (06181) falls by more than 5% again. Institutions point out that the short-term data of SKP Mall cannot represent the overall performance of same-store sales.
HK Stock Market Move | Scarce Resources (09936) surged over 16% this week, with the stock price up over 50% since the beginning of the week, validating the potential of the tantalum and niobium track in high-end prosperity verification.
Jilin Province Xidian Pharmaceutical Sci-Tech Development (301130.SZ) subsidiary obtains drug registration certificate for Vitamin B6 injection.
